Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$2.88 USD
-0.03 (-1.03%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.90 +0.02 (0.69%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 61 - 80 ( 399 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Wedbush Healthcare Conference - That''s A Wrap; Key Takeaways
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q2: EPIPHAST II Data in Q3; Delay Continues for Potential Libervant Approval
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Final EPIPHAST Data Provides Positive Surprise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Results from Final Two Arms of Part 3 of EPIPHAST; EPIPHAST II Study Underway
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Results From Final Two Arms of Part 3 of EPIPHAST; EPIPHAST II Study Underway
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Positive AQST-109 EPIPHAST Data; Equity Financing; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Initial Results from Part 3 of EPIPHAST; Additional EPIPHAST Data in Early Q3
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L